Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre Study For Evaluation Of The Efficacy And Safety Of Buprenorphine Transdermal Patch (SOVENOR Transdermal Patch 5mg And 10mg) In Patients With Non-malignant Pain Of Moderate Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint /Muscle Pain, When An Opioid Is Necessary For Obtaining Adequate Analgesia

Trial Profile

Multicentre Study For Evaluation Of The Efficacy And Safety Of Buprenorphine Transdermal Patch (SOVENOR Transdermal Patch 5mg And 10mg) In Patients With Non-malignant Pain Of Moderate Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint /Muscle Pain, When An Opioid Is Necessary For Obtaining Adequate Analgesia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Back pain; Musculoskeletal pain; Pain
  • Focus Therapeutic Use
  • Sponsors Mundipharma Pharmaceuticals Sdn Bhd

Most Recent Events

  • 13 Aug 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top